Abstract
Antibody discovery is bottlenecked by the individual expression and evaluation of antigen-specific hits. Here, we address this gap by developing an automated workflow combining cell-free DNA template generation, protein synthesis, and high-throughput binding measurements of antibody fragments in a process that takes hours rather than weeks. We apply this workflow to 119 published SARS-CoV-2 neutralizing antibodies and demonstrate rapid identification of the most potent antibody candidates.
Competing Interest Statement
A.C.H. has consulted for SwiftScale Biologics. W.K.K. and D.J.Y. are current employees of SwiftScale Biologics. M.C.J. is a cofounder of SwiftScale Biologics, Stemloop, Inc., Design Pharmaceuticals, and Pearl Bio. M.C.J.'s interests are reviewed and managed by Northwestern University in accordance with their conflict-of-interest policies. All other authors declare no competing interests.